Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Breast Cancer
    October 2025
  1. DE PASQUALE G, Donatiello V, Lucarelli M, Bonelli R, et al
    Is there an impact of autoimmune rheumatological diseases on cutaneous toxicity in breast cancer adjuvant radiotherapy? A mono-institutional experience.
    Breast Cancer. 2025 Oct 13. doi: 10.1007/s12282-025-01791.
    >> Share

  2. NISHINA T, Tanioka M, Takada K, Tsukioki T, et al
    Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer.
    Breast Cancer. 2025 Oct 12. doi: 10.1007/s12282-025-01768.
    >> Share

  3. REZAEI MH, Meymandi MS, Moslemizadeh A, Madadizadeh E, et al
    Correction: The therapeutic potential of high-intensity interval training in a breast cancer model: focus on the Hippo signaling pathway.
    Breast Cancer. 2025 Oct 10. doi: 10.1007/s12282-025-01790.
    >> Share

  4. YAMADA M, Kubo M, Kaneshiro K, Kai M, et al
    Characterization of gut microbiota dysbiosis in breast cancer patients.
    Breast Cancer. 2025 Oct 2. doi: 10.1007/s12282-025-01782.
    >> Share

  5. ZHAO X, Wang Y, Yang X, Guo H, et al
    TAMs-derived exosomes promote breast cancer progression by regulating the IRF9/IFI6 axis.
    Breast Cancer. 2025 Oct 2. doi: 10.1007/s12282-025-01789.
    >> Share

    September 2025
  6. OGITA M, Sawayanagi S, Jinnouchi H, Yoshimura M, et al
    Postmastectomy radiation therapy for implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese Breast Cancer Society Clinical Practice Guideline.
    Breast Cancer. 2025 Sep 30. doi: 10.1007/s12282-025-01788.
    >> Share

  7. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    Global mapping of artificial intelligence applications in breast cancer from 1988-2024: a machine learning approach.
    Breast Cancer. 2025 Sep 29. doi: 10.1007/s12282-025-01783.
    >> Share

  8. CELIK O, Ozgul H, Cakir RC, Lale A, et al
    Comparative analysis of level II oncoplastic surgery and conventional breast-conserving surgery in breast cancer with a ductal carcinoma in situ component.
    Breast Cancer. 2025 Sep 28. doi: 10.1007/s12282-025-01786.
    >> Share

  9. REZAEI MH, Meymandi MS, Moslemizadeh A, Madadizadeh E, et al
    The therapeutic potential of high-intensity interval training in a breast cancer model: focus on the Hippo signaling pathway.
    Breast Cancer. 2025 Sep 27. doi: 10.1007/s12282-025-01773.
    >> Share

  10. WATANABE A, Kitano S, Kato C, Tsunashima R, et al
    Pathological homogeneity and utility in the genetic diagnosis of paired mirror samples from breast cancer 10G-vacuum-assisted biopsies using a novel longitudinal dividing device.
    Breast Cancer. 2025 Sep 25. doi: 10.1007/s12282-025-01778.
    >> Share

  11. OGITA M, Sawayanagi S, Jinnouchi H, Yoshimura M, et al
    Timing of postmastectomy radiation therapy in two-stage expander/implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese breast cancer society clinical practice guideline.
    Breast Cancer. 2025 Sep 25. doi: 10.1007/s12282-025-01785.
    >> Share

  12. JIANG W, Li Y
    A dynamic nomogram predicting persistent breast cancer-related lymphedema: a retrospective cohort study in China.
    Breast Cancer. 2025 Sep 22. doi: 10.1007/s12282-025-01781.
    >> Share

  13. LI X, Huang T
    Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.
    Breast Cancer. 2025 Sep 22. doi: 10.1007/s12282-025-01779.
    >> Share

  14. FUTAMURA M, Nagao Y, Takai Y, Niwa Y, et al
    Impact of breast density on the efficacy of radiofrequency ablation in early-stage breast cancer.
    Breast Cancer. 2025 Sep 22. doi: 10.1007/s12282-025-01775.
    >> Share

  15. YAMAGUCHI-TANAKA M, Kurihara Y, Takagi K, Sato A, et al
    C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.
    Breast Cancer. 2025 Sep 12. doi: 10.1007/s12282-025-01777.
    >> Share

  16. SHIN S, Chang Y, Ryu S
    Deep learning mammography-based breast cancer risk model, its serial change, and breast cancer mortality.
    Breast Cancer. 2025 Sep 3. doi: 10.1007/s12282-025-01772.
    >> Share

  17. FANNING JE, Givant M, Chen A, Thomson S, et al
    Major anatomic variations of the lateral upper arm lymphatic pathway in a healthy female population.
    Breast Cancer. 2025;32:1125-1131.
    >> Share

  18. YAMAGUCHI T, Koyama Y, Inoue K, Ban K, et al
    Development of a deep learning-based automated diagnostic system (DLADS) for classifying mammographic lesions - a first large-scale multi-institutional clinical trial in Japan.
    Breast Cancer. 2025;32:1115-1124.
    >> Share

  19. IMAI A, Tsunashima R, Hidaka Y, Kitano S, et al
    Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.
    Breast Cancer. 2025;32:1075-1087.
    >> Share

  20. CHAROENYOTHAKUN A, Shotelersuk K, Nantavithya C, Saksornchai K, et al
    The impact of adjuvant radiotherapy on borderline and malignant phyllodes tumors of the breast.
    Breast Cancer. 2025;32:1006-1012.
    >> Share

  21. CERRAI S, Lachi A, Franchini M, Pieroni S, et al
    Alcohol consumption and breast lesions: targets for risk-based screening in high-risk Italian women.
    Breast Cancer. 2025;32:970-978.
    >> Share

    August 2025
  22. JALILI F, Hajizadeh M, Mehrabani S, Ghoreishy SM, et al
    The association between neighborhood socioeconomic status and breast cancer incidence and mortality risk: a large-scale cohort studies systematic review and meta-analysis.
    Breast Cancer. 2025 Aug 30. doi: 10.1007/s12282-025-01764.
    >> Share

  23. YE F, Chen X, Cao Y, You Z, et al
    The global, regional, and national disease burden of breast cancer attributable to behavioral risks from 1990 to 2021 and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021.
    Breast Cancer. 2025 Aug 30. doi: 10.1007/s12282-025-01771.
    >> Share

  24. KAWAMURA C, Bhaskaran K, Konishi T, Sagara Y, et al
    Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study.
    Breast Cancer. 2025 Aug 27. doi: 10.1007/s12282-025-01769.
    >> Share

  25. CHANG CC, Huang PW, Lin JC, Tsai JT, et al
    Risk factors for early-onset radiodermatitis in patients with locally advanced breast cancer: a comparative analysis of volumetric modulated arc therapy and intensity-modulated radiotherapy.
    Breast Cancer. 2025 Aug 27. doi: 10.1007/s12282-025-01762.
    >> Share

  26. OSHI M, Sasamoto M, Isoda M, Kawashima K, et al
    Patient satisfaction on prescription refill systems for breast cancer patients in Japan using a digital self-administered survey.
    Breast Cancer. 2025 Aug 26. doi: 10.1007/s12282-025-01761.
    >> Share

  27. TAKAHASHI M, Yasojima H, Osako T, Inoue K, et al
    Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis.
    Breast Cancer. 2025 Aug 21. doi: 10.1007/s12282-025-01760.
    >> Share

  28. ZHANG L, Li B, Wang R, Li J, et al
    Prospective randomized-controlled trial: efficacy of 37 degrees C-preheated thermoplastic elastomer (TPE) bolus in postoperative radiotherapy for breast cancer patients.
    Breast Cancer. 2025 Aug 20. doi: 10.1007/s12282-025-01763.
    >> Share

  29. RAY PP
    Enhancing breast cancer care through reasoning-aware LLMs: quality evaluation and risk prediction.
    Breast Cancer. 2025 Aug 20. doi: 10.1007/s12282-025-01756.
    >> Share

  30. HUNG CS, Cheng YT, Li RH, Hillman CH, et al
    Effect of exercise interventions on cognitive function in breast cancer patients and survivors: a systematic review with meta-analysis.
    Breast Cancer. 2025 Aug 18. doi: 10.1007/s12282-025-01757.
    >> Share

  31. NAHLS NS, Carpen T, Nuutinen M, Saarto T, et al
    The impact of specialist palliative care on healthcare utilization among patients with breast cancer: a nationwide register-based cohort study.
    Breast Cancer. 2025 Aug 14. doi: 10.1007/s12282-025-01759.
    >> Share

  32. MUHAMMAD UK, Sulyman SB, Saleh I, Gwarzo MY, et al
    Association of adiponectin gene polymorphism with adipokine and lipid profile in breast cancer patients from Kano, Nigeria.
    Breast Cancer. 2025 Aug 13. doi: 10.1007/s12282-025-01758.
    >> Share

  33. TAWFILES D, Chen J, Tawfiles M, Jones S, et al
    Female breast cancer burden among adolescent and young adults in North Africa.
    Breast Cancer. 2025 Aug 9. doi: 10.1007/s12282-025-01755.
    >> Share

  34. CHARALAMPOPOULOU A, Filippatos C, Malandrakis P, Zagouri F, et al
    A systematic review of the efficacy of cancer vaccines in advanced breast cancer.
    Breast Cancer. 2025 Aug 5. doi: 10.1007/s12282-025-01751.
    >> Share

  35. KITAGAWA H, Fukuzawa K, Tanaka M
    Regional disparities in breast cancer healthcare in Japan: REAL-BC study.
    Breast Cancer. 2025 Aug 2. doi: 10.1007/s12282-025-01739.
    >> Share

  36. MATSUNUMA R, Nakagaki S, Nakatani E, Kikuchi M, et al
    Impact of modified dexamethasone administration sequence on infusion reaction incidence in HER2-positive breast cancer: a randomized multicenter trial.
    Breast Cancer. 2025 Aug 2. doi: 10.1007/s12282-025-01752.
    >> Share

  37. KUBA S, Sagara Y, Yano H, Maeda S, et al
    A retrospective multi-center cohort study investigating safety of sentinel lymph node biopsy for axillary staging in clinical T3-4c breast cancer.
    Breast Cancer. 2025 Aug 1. doi: 10.1007/s12282-025-01749.
    >> Share

    July 2025
  38. HAMAMOTO Y, Makita K, Nagasaki K, Kanzaki H, et al
    Internal mammary node failure in invasive breast cancer patients who received post-operative radiotherapy without prophylactic internal mammary node irradiation.
    Breast Cancer. 2025 Jul 30. doi: 10.1007/s12282-025-01746.
    >> Share

  39. HOSHINO M, Shimoi T, Yamanaka T, Kitadai R, et al
    Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer.
    Breast Cancer. 2025 Jul 28. doi: 10.1007/s12282-025-01747.
    >> Share

  40. CHEN H, Zhou W, Zhang J, Lv J, et al
    Mapping the clinical topography and progression of venous thromboembolism in Chinese breast cancer surgical patients: a prospective longitudinal study.
    Breast Cancer. 2025 Jul 24. doi: 10.1007/s12282-025-01748.
    >> Share

  41. BANDO H, Ueda A, Terata K, Doi M, et al
    Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudi
    Breast Cancer. 2025 Jul 18. doi: 10.1007/s12282-025-01744.
    >> Share

  42. TSUKIOKI T, Takata N, Dennis SR, Terata K, et al
    Japanese translation of the Functional Assessment of Cancer Therapy-Breast + 4 (FACT-B + 4) following international guidelines: a verification of linguistic validity.
    Breast Cancer. 2025;32:773-782.
    >> Share

  43. SOWA Y, Seki H, Abe H, Komiya T, et al
    Influence of age on patient decision regret following breast reconstruction: a multicenter collaborative study in Japan.
    Breast Cancer. 2025;32:826-833.
    >> Share

  44. HARA Y, Tan PH, Foschini MP, Yano H, et al
    Polymorphous adenocarcinoma-like tumor of the breast: the first case report from Japan.
    Breast Cancer. 2025;32:867-873.
    >> Share

  45. TAKANO Y, Mizuno K, Iwase M, Morita S, et al
    Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.
    Breast Cancer. 2025;32:816-825.
    >> Share

    June 2025
  46. KUL KOPRULU T, Aras S, Erkal Cam B, Kara A, et al
    Comparison of transcriptome profiles of radiotherapy beams on MCF-7 breast cancer xenografts.
    Breast Cancer. 2025 Jun 27. doi: 10.1007/s12282-025-01735.
    >> Share

  47. HUANG M, Zhang J, Yan C, Ling R, et al
    KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.
    Breast Cancer. 2025 Jun 24. doi: 10.1007/s12282-025-01737.
    >> Share

  48. YOSHINAMI T, Takano Y, Ozaki Y, Kajiwara Y, et al
    Correction: Real?world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first? or second?line treatment for hormone receptor-positive, HER2?negative advanced or met
    Breast Cancer. 2025 Jun 23. doi: 10.1007/s12282-025-01736.
    >> Share

  49. SANLI AN, Turan B, Tekcan Sanli DE, Aydogan F, et al
    Marital status as an independent prognostic factor in male breast cancer: a SEER-based cohort study.
    Breast Cancer. 2025 Jun 16. doi: 10.1007/s12282-025-01733.
    >> Share

  50. LUO Y, Saibaidula Y, Sun Y, Ye Y, et al
    Treatment and prognosis of patients with hormone receptor-low positive (1%-10%) breast cancer: a retrospective propensity score-matched analysis.
    Breast Cancer. 2025 Jun 9. doi: 10.1007/s12282-025-01730.
    >> Share

  51. AKITA Y, Velaga R, Iwase M, Shimada S, et al
    Correction to: Prognostic impact of ER?staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
    Breast Cancer. 2025 Jun 9. doi: 10.1007/s12282-025-01729.
    >> Share

  52. ISHITOBI M, Yoshida A, Kimura Y, Sagara Y, et al
    Impact of margin status on ipsilateral breast tumor recurrence after breast-conserving treatment for patients with breast cancer who received neoadjuvant chemotherapy: a retrospective multi-institutional study of 1813 cases.
    Breast Cancer. 2025 Jun 9. doi: 10.1007/s12282-025-01732.
    >> Share

  53. TURNA M, Yildirim BA, Numanoglu C, Gul ME, et al
    Stereotactic radiosurgery for HER2-positive breast cancer brain metastases: prognostic factors and the evolving role of anti-HER2 therapies.
    Breast Cancer. 2025 Jun 8. doi: 10.1007/s12282-025-01731.
    >> Share

  54. XU G, Zhao K, Zhou X, Zhang L, et al
    Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.
    Breast Cancer. 2025 Jun 5. doi: 10.1007/s12282-025-01728.
    >> Share

  55. PENG G, Lee G, Kim S, Chen QY, et al
    Meta-analysis of smoking and breast cancer risk: by age of smoking initiation.
    Breast Cancer. 2025 Jun 3. doi: 10.1007/s12282-025-01715.
    >> Share

    May 2025
  56. SHIEN T, Nogi H, Ogiya A, Ishitobi M, et al
    Immediate breast reconstruction surgery for breast cancer: current status and future directions.
    Breast Cancer. 2025 May 26. doi: 10.1007/s12282-025-01723.
    >> Share

  57. IMOTO S, Yasojima H, Nagashima T, Onishi T, et al
    Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.
    Breast Cancer. 2025 May 25. doi: 10.1007/s12282-025-01726.
    >> Share

  58. ISOGAI A, Terada M, Wanifuchi-Endo Y, Fujita T, et al
    Optimal patient population for adjuvant S-1 therapy in hormone receptor-positive, HER2-negative early breast cancer.
    Breast Cancer. 2025 May 24. doi: 10.1007/s12282-025-01722.
    >> Share

  59. COOPER J, Airstone B, Beaman E, Carollo E, et al
    Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer.
    Breast Cancer. 2025 May 24. doi: 10.1007/s12282-025-01724.
    >> Share

  60. FUSHIMI A, Terada M, Tahara R, Nakazawa Y, et al
    Assessing the quality of Japanese online breast cancer treatment information using large language models: a comparison of ChatGPT, Claude, and expert evaluations.
    Breast Cancer. 2025 May 21. doi: 10.1007/s12282-025-01719.
    >> Share

  61. YOSHINAMI T, Takano Y, Ozaki Y, Kajiwara Y, et al
    Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic brea
    Breast Cancer. 2025 May 20. doi: 10.1007/s12282-025-01713.
    >> Share

  62. YOSHINAMI T, Shibata N, Tamaki K, Ishimaru K, et al
    Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan.
    Breast Cancer. 2025 May 19. doi: 10.1007/s12282-025-01714.
    >> Share

  63. AKITA Y, Velaga R, Iwase M, Shimada S, et al
    Prognostici of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
    Breast Cancer. 2025 May 18. doi: 10.1007/s12282-025-01716.
    >> Share

  64. LIU W, Gao F, Ma N, Zhang H, et al
    Effects of CBT-based interventions on health outcomes in breast cancer patients: a systematic review and Meta-analysis.
    Breast Cancer. 2025 May 14. doi: 10.1007/s12282-025-01711.
    >> Share

  65. USHIGUSA T, Hirakawa N, Kanomata N
    Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol.
    Breast Cancer. 2025 May 13. doi: 10.1007/s12282-025-01721.
    >> Share

  66. MIYASHITA M, Kumamaru H, Hayashi N, Kimura F, et al
    Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan.
    Breast Cancer. 2025 May 12. doi: 10.1007/s12282-025-01718.
    >> Share

  67. TAGUCHI M, Takada M, Jiaxi H, Fukui Y, et al
    Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective study.
    Breast Cancer. 2025 May 10. doi: 10.1007/s12282-025-01712.
    >> Share

  68. LU ZZ, Guo LF, Zhou J, Wu SG, et al
    A nomogram to predict the benefit of postmastectomy radiotherapy in breast cancer with nodal micrometastases.
    Breast Cancer. 2025 May 7. doi: 10.1007/s12282-025-01717.
    >> Share

  69. KAKIMI K, Sugie T
    Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.
    Breast Cancer. 2025 May 6. doi: 10.1007/s12282-025-01707.
    >> Share

  70. VENKATARAMAN J, Mokbel K
    Limitations in translating in vitro ADSC findings to clinical breast cancer risk.
    Breast Cancer. 2025 May 5. doi: 10.1007/s12282-025-01710.
    >> Share

  71. TAKAHASHI M, Minoura Y, Den H, Nomizu T, et al
    Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database.
    Breast Cancer. 2025 May 5. doi: 10.1007/s12282-025-01704.
    >> Share

  72. SOEDA I, Shibata M, Inaishi T, Ichikawa T, et al
    ATPase copper transporting beta attenuates malignant features with high expression as an indicator of favorable prognosis in breast cancer.
    Breast Cancer. 2025 May 2. doi: 10.1007/s12282-025-01705.
    >> Share

  73. LAM MC, Grufman V, Fertsch S, Recker F, et al
    Effects of breast size on breast reconstruction in BRCA mutation carriers and genetic high-risk patients after bilateral mastectomy.
    Breast Cancer. 2025;32:582-595.
    >> Share

  74. WU Q, He J, Herrler T, Yu B, et al
    Adipose-derived stem cells enhance the tumorigenic potential of pre-malignant breast epithelial cells through paracrine activation of PI3K-AKT pathway.
    Breast Cancer. 2025;32:552-565.
    >> Share

  75. MATSUBARA Y, Suganuma N, Nakamoto S, Kikawa Y, et al
    Repeated sentinel lymph node biopsy for local recurrence after breast-conserving surgery.
    Breast Cancer. 2025;32:512-519.
    >> Share

    April 2025
  76. KONISHI T, Kumamaru H, Niikura N, Sagara Y, et al
    Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status.
    Breast Cancer. 2025 Apr 21. doi: 10.1007/s12282-025-01698.
    >> Share

  77. USHIGUSA T, Yoshida A, Kanomata N
    Reply to the letter to the editor "Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients".
    Breast Cancer. 2025 Apr 13. doi: 10.1007/s12282-025-01703.
    >> Share

  78. DING X, Zhu M, Kan H, Wang Q, et al
    Relationship between psychological resilience and cognitive function on breast cancer chemotherapy patients: a person-centered method.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01697.
    >> Share

  79. JO A, Iwamoto T, Suzuki Y, Ogata R, et al
    Validation of the Symptom Illustration Scale within an electronic Patient-Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01702.
    >> Share

  80. WATANUKI R, Sakai H, Takehara Y, Yoshida A, et al
    Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01700.
    >> Share

  81. MIZUTA M, Okumura M, Inoue J, Ueda Y, et al
    Association between preoperative grip strength and postoperative upper extremity impairments in patients with breast cancer: a retrospective cohort study.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01699.
    >> Share

  82. NAGAI SE, Hattori M, Yoshinami T, Masuda H, et al
    Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
    Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01689.
    >> Share

  83. MAN V, Duan J, Luk WP, Fung LH, et al
    Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes.
    Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01692.
    >> Share

  84. SONG N, Yang K, Li Y
    Constructing shared genetic architecture between bioavailable testosterone and luminal A breast cancer in female.
    Breast Cancer. 2025 Apr 3. doi: 10.1007/s12282-025-01696.
    >> Share

  85. UEMATSU M, Nakajima H, Miyake H, Wakabayashi M, et al
    Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.
    Breast Cancer. 2025 Apr 2. doi: 10.1007/s12282-025-01694.
    >> Share

    March 2025
  86. GARCIA-CHICO C, Lopez-Ortiz S, Lorenzo-Crespo C, Pinto-Fraga J, et al
    Wrapping up the evidence: bandaging in breast cancer-related lymphedema-a systematic review and meta-analysis.
    Breast Cancer. 2025 Mar 31. doi: 10.1007/s12282-025-01693.
    >> Share

  87. TOI M
    Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer.
    Breast Cancer. 2025 Mar 27. doi: 10.1007/s12282-025-01695.
    >> Share

  88. SOTA Y, Seno S, Naoi Y, Honma K, et al
    IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses.
    Breast Cancer. 2025 Mar 24. doi: 10.1007/s12282-025-01687.
    >> Share

  89. WANG SJ, Feng X, Zhang W, Fang H, et al
    Specific types of anxiety regarding radiation therapy in patients with breast cancer: a longitudinal study.
    Breast Cancer. 2025 Mar 23. doi: 10.1007/s12282-025-01690.
    >> Share

  90. USHIGUSA T, Hirakawa N, Kajiura Y, Yoshida A, et al
    Correction: Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.
    Breast Cancer. 2025 Mar 17. doi: 10.1007/s12282-025-01688.
    >> Share

  91. DONG C, Sun Y, Xu X, Li H, et al
    c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERalpha: the central role of miR-152 and miR-148a.
    Breast Cancer. 2025 Mar 3. doi: 10.1007/s12282-025-01683.
    >> Share

  92. SATO K, Fuchikami H, Takeda N, Natsume N, et al
    Long-term local control and cosmesis of perioperative interstitial brachytherapy for partial breast irradiation following breast-conserving surgery.
    Breast Cancer. 2025;32:447-455.
    >> Share

  93. FARHAT J, Sakai H, Tsurutani J
    Management of nausea and vomiting induced by antibody-drug conjugates.
    Breast Cancer. 2025;32:278-285.
    >> Share

  94. NAKATSUKA K, Karakawa R, Yano T
    Color differences of skin paddles using the free flap for autologous breast reconstruction in Asian patients.
    Breast Cancer. 2025;32:306-313.
    >> Share

    February 2025
  95. WU SI, Chen VC, Hsu YH, Tzang BS, et al
    Contemporaneous changes in cytokines and cognitive function during chemotherapy in patients with breast cancer: a prospective follow-up study.
    Breast Cancer. 2025 Feb 25. doi: 10.1007/s12282-025-01668.
    >> Share

  96. NATORI K, Igeta M, Morimoto T, Nagahashi M, et al
    Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters.
    Breast Cancer. 2025 Feb 20. doi: 10.1007/s12282-025-01678.
    >> Share

  97. ANDO Y, Masuda T, Hayashi N, Kosai K, et al
    SET-binding protein 1 (SETBP1) suppresses cell proliferation in estrogen receptor-positive breast cancer.
    Breast Cancer. 2025 Feb 20. doi: 10.1007/s12282-025-01667.
    >> Share

  98. KAWASHIMA K, Narui K, Nishikawa A, Sasamoto M, et al
    The impact of axillary lymph-node dissection omission on adjuvant abemaciclib eligibility in HR-positive, HER2-negative breast cancer with positive sentinel lymph nodes.
    Breast Cancer. 2025 Feb 20. doi: 10.1007/s12282-025-01684.
    >> Share

  99. KIM SH, Oh JM, Kim YJ, Kim J, et al
    Postoperative cholesterol changes as early predictors of breast cancer-related lymphedema: a retrospective cohort study.
    Breast Cancer. 2025 Feb 18. doi: 10.1007/s12282-025-01682.
    >> Share

  100. NISHIMURA R, Sagara Y, Mitsueda R, Taira T, et al
    A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer.
    Breast Cancer. 2025 Feb 18. doi: 10.1007/s12282-025-01677.
    >> Share

  101. RIZK M, Mokbel K
    Refining the role of surgery in de novo stage IV breast cancer: the need for biomarkers and mechanistic insights.
    Breast Cancer. 2025 Feb 17. doi: 10.1007/s12282-025-01681.
    >> Share

  102. NAKAYAMA S, Iwamoto T, Araki K, Narui K, et al
    A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy.
    Breast Cancer. 2025 Feb 10. doi: 10.1007/s12282-025-01680.
    >> Share

  103. HARA A, Ozaki A, Murakami M, Saito H, et al
    Breast cancer screening rates and influencing factors among LGBTQ groups in Japan.
    Breast Cancer. 2025 Feb 8. doi: 10.1007/s12282-025-01669.
    >> Share

  104. NAGAHASHI M, Kumamaru H, Kinukawa N, Iwamoto T, et al
    Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression.
    Breast Cancer. 2025 Feb 6. doi: 10.1007/s12282-025-01671.
    >> Share

  105. TOKUNAGA E, Koi Y, Tajiri W, Koga C, et al
    The impact of breast surgery and systemic therapy on the survival of patients with de novo stage IV breast cancer.
    Breast Cancer. 2025 Feb 2. doi: 10.1007/s12282-025-01675.
    >> Share

    January 2025
  106. ONDER T, Karacin C
    NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life.
    Breast Cancer. 2025 Jan 31. doi: 10.1007/s12282-025-01676.
    >> Share

  107. PARK MS, Cho EH, Youn Y, Do IG, et al
    Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients.
    Breast Cancer. 2025 Jan 31. doi: 10.1007/s12282-025-01673.
    >> Share

  108. ALTUNDAG K
    Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.
    Breast Cancer. 2025 Jan 29. doi: 10.1007/s12282-025-01672.
    >> Share

  109. NAGAHASHI M, Ishikawa E, Nagai T, Kanaoka H, et al
    Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer. 2025 Jan 14. doi: 10.1007/s12282-025-01665.
    >> Share

  110. IWABUCHI E, Miki Y, Xu J, Kanai A, et al
    Tetraspanins CD63 and CD81 as potential prognostic biomarkers in breast cancer.
    Breast Cancer. 2025 Jan 14. doi: 10.1007/s12282-025-01666.
    >> Share

  111. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
    Impact of breast size and composition on the accuracy of mammography and ultrasonography in breast cancer screening.
    Breast Cancer. 2025 Jan 2. doi: 10.1007/s12282-024-01664.
    >> Share

  112. TAKAHASHI K, Kagami Y, Yoshimura R, Morota M, et al
    Prospective study of once-daily accelerated partial breast irradiation using 3-dimensional conformal external beam radiotherapy for Japanese women: 12-year outcomes, toxicity, and cosmesis.
    Breast Cancer. 2025;32:197-207.
    >> Share

  113. NAKAYAMA S, Yoshizawa A, Tsurutani J, Yoshimura K, et al
    Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).
    Breast Cancer. 2025;32:177-185.
    >> Share

  114. SUNG YN, Jeon T, Lee JY, Oh J, et al
    Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.
    Breast Cancer. 2025;32:186-196.
    >> Share

  115. BEHRENS AS, Huebner H, Haberle L, Stamminger M, et al
    Comparative assessment of breast volume using a smartphone device versus MRI.
    Breast Cancer. 2025;32:166-176.
    >> Share

  116. GARG S, Rai G, Singh S, Gauba P, et al
    An insight into the role of innate immune cells in breast tumor microenvironment.
    Breast Cancer. 2025;32:79-100.
    >> Share

  117. TAN E, Chong J, Pua U, Tan EY, et al
    Local recurrence and residual tumor rates following cryoablation for small early-stage breast cancers: systemic review and meta-analysis.
    Breast Cancer. 2025;32:69-78.
    >> Share

    December 2024
  118. USHIGUSA T, Hirakawa N, Kajiura Y, Yoshida A, et al
    Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.
    Breast Cancer. 2024 Dec 27. doi: 10.1007/s12282-024-01662.
    >> Share

  119. LIU P, Liu D, Zhao C, Wei Y, et al
    Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study.
    Breast Cancer. 2024 Dec 27. doi: 10.1007/s12282-024-01663.
    >> Share

  120. PARK YS, Jang SI, Shin J, Nam CM, et al
    Factors associated with post acute care utilization after mastectomy for breast cancer patients.
    Breast Cancer. 2024 Dec 19. doi: 10.1007/s12282-024-01659.
    >> Share

  121. KAKUMOTO A, Jamiyan T, Koyanagi A, Kuroda H, et al
    Prognostic impact of tumor?associated stroma in triple-negative breast cancer.
    Breast Cancer. 2024 Dec 18. doi: 10.1007/s12282-024-01661.
    >> Share

  122. BATOOL Z, Kamal MA, Shen B
    Evidence-based advancements in breast cancer genetic counseling: a review.
    Breast Cancer. 2024 Dec 17. doi: 10.1007/s12282-024-01660.
    >> Share

  123. HATTORI M
    Role of circulating tumor cells in breast cancer.
    Breast Cancer. 2024 Dec 10. doi: 10.1007/s12282-024-01651.
    >> Share

  124. GAMBA G, Colonetti T, Uggioni MLR, Elibio LU, et al
    Gut microbiota and breast cancer: systematic review and meta-analysis.
    Breast Cancer. 2024 Dec 9. doi: 10.1007/s12282-024-01658.
    >> Share

  125. AOYAMA Y, Ozaki Y, Kizawa R, Masuda J, et al
    Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.
    Breast Cancer. 2024 Dec 7. doi: 10.1007/s12282-024-01657.
    >> Share

  126. MORITA M, Tsunashima R, Yoshinami T, Ishida M, et al
    A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients.
    Breast Cancer. 2024 Dec 4. doi: 10.1007/s12282-024-01656.
    >> Share

    November 2024
  127. OTANI Y, Tanaka A, Maekawa M, Pena T, et al
    The role of C1orf50 in breast cancer progression and prognosis.
    Breast Cancer. 2024 Nov 28. doi: 10.1007/s12282-024-01653.
    >> Share

  128. KATZ D, Feldhamer I, Wolff-Sagy Y, Goldvaser H, et al
    Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-gene recurrence score (> 25): a 10-year follow-up in a real-world cohort.
    Breast Cancer. 2024 Nov 27. doi: 10.1007/s12282-024-01652.
    >> Share

  129. GUO R, Wang P
    The complex role of regulatory cells in breast cancer: implication for immunopathogenesis and immunotherapy.
    Breast Cancer. 2024 Nov 26. doi: 10.1007/s12282-024-01654.
    >> Share

  130. XU Q, Li X, Yuan Y, Hu Z, et al
    Development and validation of a predictive risk tool for VTE in women with breast cancer under chemotherapy: a cohort study in China.
    Breast Cancer. 2024 Nov 16. doi: 10.1007/s12282-024-01646.
    >> Share

  131. NASHIMOTO M, Asano Y, Matsui H, Machida Y, et al
    Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.
    Breast Cancer. 2024;31:1010-1017.
    >> Share

  132. YOSHIDA R, Kaneyasu T, Ueki A, Yamauchi H, et al
    High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.
    Breast Cancer. 2024;31:1028-1036.
    >> Share

    October 2024
  133. TADA H, Miyashita M, Harada-Shoji N, Ebata A, et al
    Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan.
    Breast Cancer. 2024 Oct 28. doi: 10.1007/s12282-024-01639.
    >> Share

  134. WANG X, Zhang X, Zhang L, Meng J, et al
    Clinical outcomes after post-operative radiotherapy for breast cancer patients presenting with ipsilateral supraclavicular metastasis: considerations on the cranial border of irradiation field.
    Breast Cancer. 2024 Oct 23. doi: 10.1007/s12282-024-01644.
    >> Share

  135. TOKUNAGA E, Iwata H, Itoh M, Taira T, et al
    Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
    Breast Cancer. 2024 Oct 8. doi: 10.1007/s12282-024-01640.
    >> Share

  136. HAO J, Remis A, Zhu D, Yao Y, et al
    Mirror therapy for patients with breast cancer: A systematic review and meta-analysis.
    Breast Cancer. 2024 Oct 5. doi: 10.1007/s12282-024-01642.
    >> Share

  137. TAKATORI-SHIRAKAMI Y, Saito M, Yokoyama K
    Economic impact of screening on postdiagnosis work productivity in Japanese women with breast cancer: a life-table modeling approach.
    Breast Cancer. 2024 Oct 4. doi: 10.1007/s12282-024-01637.
    >> Share

  138. KAWAI Y, Nagayama A, Miyao K, Takeuchi M, et al
    A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer.
    Breast Cancer. 2024 Oct 1. doi: 10.1007/s12282-024-01641.
    >> Share

    September 2024
  139. KWON MR, Ko EY, Lee JE, Han BK, et al
    Prediction model for individualized precision surgery in breast cancer patients with complete response on MRI and residual calcifications on mammography after neoadjuvant chemotherapy.
    Breast Cancer. 2024 Sep 30. doi: 10.1007/s12282-024-01638.
    >> Share

  140. HUANG Q, Wang J, Ning H, Liu W, et al
    Integrin beta1 in breast cancer: mechanisms of progression and therapy.
    Breast Cancer. 2024 Sep 30. doi: 10.1007/s12282-024-01635.
    >> Share

  141. MICHAELI JC, Michaeli T, Trapani D, Albers S, et al
    Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Breast Cancer. 2024 Sep 25. doi: 10.1007/s12282-024-01634.
    >> Share

  142. ABE T, Kataoka A, Uehiro N, Yoshida N, et al
    Desire for pregnancy and fertility preservation in young patients with breast cancer.
    Breast Cancer. 2024 Sep 25. doi: 10.1007/s12282-024-01633.
    >> Share

  143. ENDO Y, Kotani H, Tamura N, Tanaka K, et al
    Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy.
    Breast Cancer. 2024 Sep 23. doi: 10.1007/s12282-024-01630.
    >> Share

  144. NAKAYAMA T, Niikura N, Yamanaka T, Yamamoto M, et al
    Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
    Breast Cancer. 2024 Sep 20. doi: 10.1007/s12282-024-01632.
    >> Share

  145. WANG RJ, Liu HY, Guo LF, Yu D, et al
    21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer.
    Breast Cancer. 2024 Sep 19. doi: 10.1007/s12282-024-01636.
    >> Share

  146. JITWATCHARAKOMOL T, Setakornnukul J, Chuthatisith S, Ratanawichitrasin A, et al
    Non-irradiated area of intraoperative radiotherapy with electron technique: outcomes and pattern of failure in early-stage breast cancer from a single-center, registry study.
    Breast Cancer. 2024 Sep 10. doi: 10.1007/s12282-024-01624.
    >> Share

  147. SASADA S, Kumamaru H, Hayashi N, Kinukawa N, et al
    Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry.
    Breast Cancer. 2024;31:909-916.
    >> Share

  148. MIYAZAWA K, Satake T, Muto M, Tsunoda Y, et al
    Delayed breast reconstruction with autologous free flap after radiation therapy: vascular complications and aesthetic outcomes.
    Breast Cancer. 2024;31:798-806.
    >> Share

  149. BELLINI C, Pugliese F, Bicchierai G, Amato F, et al
    Contrast-enhanced mammography in the management of breast architectural distortions and avoidance of unnecessary biopsies.
    Breast Cancer. 2024;31:851-857.
    >> Share

  150. SEKI H, Sasada S, Shien T
    Reply to the Letter to the editor "Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?".
    Breast Cancer. 2024 Sep 1. doi: 10.1007/s12282-024-01629.
    >> Share

    August 2024
  151. CHANG YT, Hong ZJ, Tsai HH, Feng AC, et al
    Hub metastatic gene signature and risk score of breast cancer patients with small tumor sizes using WGCNA.
    Breast Cancer. 2024 Aug 27. doi: 10.1007/s12282-024-01627.
    >> Share

  152. GANATRA H, Tan JK, Simmons A, Bigogno CM, et al
    Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape.
    Breast Cancer. 2024 Aug 27. doi: 10.1007/s12282-024-01628.
    >> Share

  153. KITADAI R, Shimoi T, Yazaki S, Okuma HS, et al
    Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
    Breast Cancer. 2024 Aug 14. doi: 10.1007/s12282-024-01617.
    >> Share

  154. WATANABE M, Fujiki S, Okura Y, Toshikawa C, et al
    Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.
    Breast Cancer. 2024 Aug 13. doi: 10.1007/s12282-024-01623.
    >> Share

  155. NAKAYAMA T, Niikura N, Yamanaka T, Yamamoto M, et al
    Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
    Breast Cancer. 2024 Aug 12. doi: 10.1007/s12282-024-01614.
    >> Share

  156. RAHMANI F, Ajoudanifar H, Arbab Soleimani N, Imani Fooladi AA, et al
    Targeted therapies in HER2-positive breast cancer with receptor-redirected Arazyme-linker-Herceptin as a novel fusion protein.
    Breast Cancer. 2024 Aug 9. doi: 10.1007/s12282-024-01625.
    >> Share

  157. RUIZ JI, Lei X, Chi-Fang W, Giordano SH, et al
    Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors.
    Breast Cancer. 2024 Aug 8. doi: 10.1007/s12282-024-01618.
    >> Share

  158. NAKAMURA M, Fujisawa T, Oyoshi H, Zhou Y, et al
    Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC).
    Breast Cancer. 2024 Aug 8. doi: 10.1007/s12282-024-01626.
    >> Share

  159. CHEN YA, Lai HW, Su HC, Loh EW, et al
    Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data.
    Breast Cancer. 2024 Aug 1. doi: 10.1007/s12282-024-01622.
    >> Share

    July 2024
  160. UEZONO H, Onoe T, Shikama N, Ono Y, et al
    Uptake of ultra-hypofractionated radiation therapy following breast-conserving surgery among patients with early-stage breast cancer: a multi-institutional questionnaire survey.
    Breast Cancer. 2024 Jul 24. doi: 10.1007/s12282-024-01621.
    >> Share

  161. ALTUNDAG K
    Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?
    Breast Cancer. 2024 Jul 20. doi: 10.1007/s12282-024-01620.
    >> Share

  162. HU Z, Lai C, Liu H, Man J, et al
    Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort.
    Breast Cancer. 2024 Jul 19. doi: 10.1007/s12282-024-01619.
    >> Share

  163. SHIBATA A, Tamura N, Kinowaki K, Nishikawa A, et al
    Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
    Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01616.
    >> Share

  164. HOSONAGA M, Habano E, Arakawa H, Kaneko K, et al
    Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
    Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01612.
    >> Share

  165. PINELLI F, Barbani F, Defilippo B, Fundaro A, et al
    Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-port.
    Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01608.
    >> Share

  166. NAKAMOTO S, Iwamoto T, Taira N, Kajiwara Y, et al
    The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10.
    Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01610.
    >> Share

  167. WEI JF, Li F, Lin JW, Dou ZA, et al
    Development and validation of a neoadjuvant chemotherapy pathological complete remission model based on Reg IV expression in breast cancer tissues: a clinical retrospective study.
    Breast Cancer. 2024 Jul 8. doi: 10.1007/s12282-024-01609.
    >> Share

  168. LUO Y, Chen X, Lv R, Li Q, et al
    Breast-conserving surgery versus modified radical mastectomy in T1-2N3M0 stage breast cancer: a propensity score matching analysis.
    Breast Cancer. 2024 Jul 8. doi: 10.1007/s12282-024-01611.
    >> Share

  169. KOYAMA Y, Nakashima K, Orihara S, Tsunoda H, et al
    Inter- and intra-observer variability of qualitative visual breast-composition assessment in mammography among Japanese physicians: a first multi-institutional observer performance study in Japan.
    Breast Cancer. 2024;31:671-683.
    >> Share

  170. MAITA KC, Avila FR, Torres-Guzman RA, Garcia JP, et al
    The usefulness of artificial intelligence in breast reconstruction: a systematic review.
    Breast Cancer. 2024;31:562-571.
    >> Share

  171. KATO S, Mori H, Saiga M, Watanabe S, et al
    Nipple-areolar complex malposition in breast reconstruction after nipple-sparing mastectomy: a multi-institutional retrospective observational study in Japan.
    Breast Cancer. 2024;31:649-658.
    >> Share

    June 2024
  172. WANG B, Chu H, Wei S, Hsu H, et al
    Exploration of treatment strategies and susceptibility gene of postoperative nausea and vomiting in breast cancer patients: a randomised controlled trial.
    Breast Cancer. 2024 Jun 19. doi: 10.1007/s12282-024-01606.
    >> Share

  173. SEKI H, Ogiya A, Nagura N, Shimo A, et al
    Prognosis of isolated locoregional recurrence after early breast cancer with immediate breast reconstruction surgery: a retrospective multi?institutional study.
    Breast Cancer. 2024 Jun 19. doi: 10.1007/s12282-024-01607.
    >> Share

  174. YAMASHITA T, Sohn JH, Tokunaga E, Niikura N, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
    Breast Cancer. 2024 Jun 17. doi: 10.1007/s12282-024-01600.
    >> Share

  175. HUANG Y, Ke C, Cai J, Wei X, et al
    Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer.
    Breast Cancer. 2024 Jun 15. doi: 10.1007/s12282-024-01605.
    >> Share

  176. TELLI ML, Litton JK, Beck JT, Jones JM, et al
    Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
    Breast Cancer. 2024 Jun 13. doi: 10.1007/s12282-024-01603.
    >> Share

  177. KITANO S, Tsunashima R, Kato C, Watanabe A, et al
    Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
    Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01602.
    >> Share

  178. PURJA S, Nguyen DT, Kim E
    Breast cancer epigenetics: current and evolving treatment.
    Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01601.
    >> Share

  179. CHEN Y, Zhou Y, Chen J, Yang J, et al
    Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression.
    Breast Cancer. 2024 Jun 4. doi: 10.1007/s12282-024-01574.
    >> Share

    May 2024
  180. MUR-GIMENO E, Coll M, Yuguero-Ortiz A, Navarro M, et al
    Comparison of water- vs. land-based exercise for improving functional capacity and quality of life in patients living with and beyond breast cancer (the AQUA-FiT study): a randomized controlled trial.
    Breast Cancer. 2024 May 30. doi: 10.1007/s12282-024-01596.
    >> Share

  181. TENG L, Du J, Yan S, Xu P, et al
    A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.
    Breast Cancer. 2024 May 27. doi: 10.1007/s12282-024-01591.
    >> Share

  182. OKUYAMA H, Takada F, Taira N, Nakamura S, et al
    A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy.
    Breast Cancer. 2024 May 26. doi: 10.1007/s12282-024-01592.
    >> Share

  183. KATARIA M, Gupta N, Kumar A, Bhoriwal S, et al
    Assessing the effectiveness of high frequency repetitive transcranial magnetic stimulation for post-mastectomy pain in breast cancer patients: A randomized controlled trial.
    Breast Cancer. 2024 May 26. doi: 10.1007/s12282-024-01598.
    >> Share

  184. FRANCESCHI BT, Bezerra PHA, Torqueti MR
    Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.
    Breast Cancer. 2024 May 23. doi: 10.1007/s12282-024-01590.
    >> Share

  185. JEZEQUEL P, Lasla H, Gouraud W, Basseville A, et al
    Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
    Breast Cancer. 2024 May 22. doi: 10.1007/s12282-024-01597.
    >> Share

  186. ALTUNDAG K
    Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density.
    Breast Cancer. 2024 May 18. doi: 10.1007/s12282-024-01595.
    >> Share

  187. DURAN S, Varol U, Tekir O, Soyturk AH, et al
    Resilience's impact on quality of life and post-traumatic growth in breast cancer patients during treatment.
    Breast Cancer. 2024 May 17. doi: 10.1007/s12282-024-01594.
    >> Share

  188. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 May 12. doi: 10.1007/s12282-024-01589.
    >> Share

  189. BAO YQ, Yu TH, Huang W, Mao QF, et al
    Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients.
    Breast Cancer. 2024 May 5. doi: 10.1007/s12282-024-01588.
    >> Share

  190. VAN ROOIJ JAF, Bijkerk E, van der Hulst RRJW, Tuinder SMH, et al
    The influence of a previous implant-based breast reconstruction on postoperative sensation of the deep inferior epigastric artery perforator flap.
    Breast Cancer. 2024;31:456-466.
    >> Share

  191. NOGI H, Ogiya A, Ishitobi M, Yamauchi C, et al
    Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
    Breast Cancer. 2024;31:507-518.
    >> Share

  192. CH'NG ES
    Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.
    Breast Cancer. 2024;31:496-506.
    >> Share

  193. TSUCHIDA Y, Niikura N, Chishima T, Mizuno M, et al
    Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX(R) test data: a retrospective multicenter study in Japan.
    Breast Cancer. 2024;31:401-408.
    >> Share

  194. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
    Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
    Breast Cancer. 2024;31:536-538.
    >> Share

    April 2024
  195. SHIMOMURA A, Sagara Y, Koto R, Fujiwara M, et al
    Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.
    Breast Cancer. 2024 Apr 29. doi: 10.1007/s12282-024-01572.
    >> Share

  196. KAWAMOTO H, Tsugawa K, Furuya Y, Sakamaki K, et al
    Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan.
    Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01584.
    >> Share

  197. LEE SJ, Cha CD, Hong H, Choi YY, et al
    Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01586.
    >> Share

  198. YANG PJ, Tsai EM, Hou MF, Lee YJ, et al
    Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors.
    Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01579.
    >> Share

  199. YOSHINAMI T
    Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy.
    Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01571.
    >> Share

  200. ALTUNDAG K
    Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients.
    Breast Cancer. 2024 Apr 22. doi: 10.1007/s12282-024-01587.
    >> Share

  201. SHANG Y, Wang X, Liu Y, Cheng W, et al
    Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
    Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01583.
    >> Share

  202. NA S, Kim M, Park Y, Kwon HJ, et al
    Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.
    Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01585.
    >> Share

  203. YOSHINAMI T, Nagai SE, Hattori M, Okamura T, et al
    Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or seco
    Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575.
    >> Share

  204. ROUSSET-JABLONSKI C, Lortal B, Lantheaume S, Arnould L, et al
    French national survey on breast cancer care: caregiver and patient views.
    Breast Cancer. 2024 Apr 18. doi: 10.1007/s12282-024-01576.
    >> Share

  205. ZHANG HP, Jiang RY, Zhu JY, Sun KN, et al
    PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Breast Cancer. 2024 Apr 17. doi: 10.1007/s12282-024-01567.
    >> Share

  206. TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
    Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
    Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
    >> Share

  207. DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
    Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
    >> Share

  208. SUZUKI K, Morishita S, Nakano J, Okayama T, et al
    Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
    >> Share

  209. WATANABE A, Tsunashima R, Kato C, Kitano S, et al
    Investigation of recurrence prediction ability of EndoPredict((R)) using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to FFPE
    Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
    >> Share

  210. YOSHIMURA M, Yamauchi C, Sanuki N, Hamamoto Y, et al
    The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.
    Breast Cancer. 2024 Apr 5. doi: 10.1007/s12282-024-01568.
    >> Share

  211. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 Apr 3. doi: 10.1007/s12282-024-01566.
    >> Share

  212. LIN D, Sturgeon KM, Muscat JE, Zhou S, et al
    Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
    Breast Cancer. 2024 Apr 2. doi: 10.1007/s12282-024-01569.
    >> Share

  213. YE JH, Yu J, Huang MY, Mo YM, et al
    The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
    Breast Cancer. 2024 Apr 1. doi: 10.1007/s12282-024-01553.
    >> Share

    March 2024
  214. OCHIYA T, Hashimoto K, Shimomura A
    Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer.
    Breast Cancer. 2024 Mar 30. doi: 10.1007/s12282-024-01563.
    >> Share

  215. NARUI K, Satake T, Ishikawa T, Muto M, et al
    Endoscopic mastectomy followed by immediate breast reconstruction with fat grafting for breast cancer.
    Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01561.
    >> Share

  216. HASHIMOTO K, Ochiya T, Shimomura A
    Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management.
    Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01562.
    >> Share

  217. VO K, Ladbury C, Yoon S, Bazan J, et al
    Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
    Breast Cancer. 2024 Mar 20. doi: 10.1007/s12282-024-01560.
    >> Share

  218. OHMURA H, Hanamura F, Okumura Y, Ando Y, et al
    Liquid biopsy for breast cancer and other solid tumors: a review of recent advances.
    Breast Cancer. 2024 Mar 16. doi: 10.1007/s12282-024-01556.
    >> Share

  219. HU X
    The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
    Breast Cancer. 2024 Mar 14. doi: 10.1007/s12282-024-01557.
    >> Share

  220. LI G, Lin X, Wang X, Cai L, et al
    Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01554.
    >> Share

  221. KANG D, Park S, Kim HJ, Lee J, et al
    Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01559.
    >> Share

  222. KIDA K, Yamada A, Shimada K, Narui K, et al
    A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Breast Cancer. 2024 Mar 8. doi: 10.1007/s12282-024-01551.
    >> Share

  223. OBA K, Adachi M, Kobayashi T, Takaya E, et al
    Deep learning model to predict Ki-67 expression of breast cancer using digital breast tomosynthesis.
    Breast Cancer. 2024 Mar 7. doi: 10.1007/s12282-024-01549.
    >> Share

  224. HATTORI M, Honma N, Nagai S, Narui K, et al
    Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
    Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01550.
    >> Share

  225. KASAHARA M, Kanematsu S, Tanaka Y, Okazaki S, et al
    Clinical benefits of tomosynthesis-guided vacuum assisted breast biopsy: a comparison with stereotactic vacuum assisted biopsy.
    Breast Cancer. 2024;31:329-334.
    >> Share

  226. WU X, Gui Y, Liu J, Li S, et al
    Patient-reported outcomes of mesh in minimally invasive (laparoscopic/robot-assisted) immediate subpectoral prosthesis breast reconstruction: a retrospective study.
    Breast Cancer. 2024;31:243-251.
    >> Share

  227. WONG HH, Cojocaru E, Watkins J, James S, et al
    Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.
    Breast Cancer. 2024;31:272-282.
    >> Share

  228. AOYAMA Y, Hoshino E, Shimomura A, Shimizu C, et al
    Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
    Breast Cancer. 2024;31:234-242.
    >> Share

  229. CHEN BF, Tsai YF, Lien PJ, Lin YS, et al
    Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
    Breast Cancer. 2024;31:217-227.
    >> Share

  230. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
    The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening.
    Breast Cancer. 2024;31:228-233.
    >> Share

    February 2024
  231. PARIJA M, Prakash S, Krishna BM, Dash S, et al
    SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor beta.
    Breast Cancer. 2024 Feb 29. doi: 10.1007/s12282-024-01555.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016